This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Hammer H., Ebert B., Jensen H.S., Jensen A.A.:Functional characterization of the 1,5-benzodiazepine clobazam and its major active metabolite N-desmethylclobazam at human GABA(A) receptors expressed in Xenopus laevis oocytes. PLoS One, 2015 Mar 23; 10 (3): e0120239. doi: 10.1371/journal.pone.0120239. PMID: 25798598; PMCID: PMC4370687.HammerH.EbertB.JensenH.S.JensenA.A.Functional characterization of the 1,5-benzodiazepine clobazam and its major active metabolite N-desmethylclobazam at human GABA(A) receptors expressed in Xenopus laevis oocytesPLoS One2015Mar23103e012023910.1371/journal.pone.012023925798598PMC4370687Open DOISearch in Google Scholar
Huddart R., Leeder J.S., Altman R.B., Klein T.E.:PharmGKB summary: clobazam pathway, pharmacokinetics. Pharmacogenet Genomics, 2018, 28: 110–115. doi: 10.1097/FPC.0000000000000327. PMID: 29517622; PMCID: PMC5914180.HuddartR.LeederJ.S.AltmanR.B.KleinT.E.PharmGKB summary: clobazam pathway, pharmacokineticsPharmacogenet Genomics20182811011510.1097/FPC.000000000000032729517622PMC5914180Open DOISearch in Google Scholar
Madžar D., Geyer A., Knappe R.U., Gollwitzer S., Kuramatsu J.B., Gerner S.T. et al.:Effects of clobazam for treatment of refractory status epilepticus. BMC Neurol., 2016, 16: 202. doi: 10.1186/s12883-016-0724-y. PMID: 27769254; PMCID: PMC5073816.MadžarD.GeyerA.KnappeR.U.GollwitzerS.KuramatsuJ.B.GernerS.T.Effects of clobazam for treatment of refractory status epilepticusBMC Neurol.20161620210.1186/s12883-016-0724-y27769254PMC5073816Open DOISearch in Google Scholar
Maille J.M., Hanna S.S., Shah D.N.:Addition of clobazam successfully treating drug resistant seizures in Heidenhain variant Creutzfeldt Jakob disease: A case report. Epilepsy Behav. Rep., 2023, 21: 100585. doi: 10.1016/j.ebr.2023.100585. PMID: 36698381; PMCID: PMC9867951.MailleJ.M.HannaS.S.ShahD.N.Addition of clobazam successfully treating drug resistant seizures in Heidenhain variant Creutzfeldt Jakob disease: A case reportEpilepsy Behav. Rep.20232110058510.1016/j.ebr.2023.10058536698381PMC9867951Open DOISearch in Google Scholar
Marawar R., Basha M., Mahulikar A., Desai A., Suchdev K., Shah A.:Updates in Refractory Status Epilepticus. Crit Care Res Pract, 2018; 2018: 9768949. doi: 10.1155/2018/9768949. PMID: 29854452; PMCID: PMC5964484.MarawarR.BashaM.MahulikarA.DesaiA.SuchdevK.ShahA.Updates in Refractory Status EpilepticusCrit Care Res Pract20182018976894910.1155/2018/976894929854452PMC5964484Open DOISearch in Google Scholar
Sankar R.:GABA(A) receptor physiology and its relationship to the mechanism of action of the 1,5-benzodiazepine clobazam. CNS Drugs, 2012, 26: 229–44. doi: 10.2165/11599020-000000000-00000. PMID: 22145708.SankarR.GABA(A) receptor physiology and its relationship to the mechanism of action of the 1,5-benzodiazepine clobazamCNS Drugs2012262294410.2165/11599020-000000000-0000022145708Open DOISearch in Google Scholar
Sivakumar S., Ibrahim M., Parker D. Jr, Norris G., Shah A., Mohamed W.:Clobazam: An effective add-on therapy in refractory status epilepticus. Epilepsia, 2015, 56: e83–9. doi: 10.1111/epi.13013. Epub 2015 May 12. PMID: 25963810.SivakumarS.IbrahimM.ParkerD.JrNorrisG.ShahA.MohamedW.Clobazam: An effective add-on therapy in refractory status epilepticusEpilepsia201556e83910.1111/epi.13013Epub 2015 May 12.25963810Open DOISearch in Google Scholar
Storustovu S.I., Ebert B.:Pharmacological characterization of agonists at delta-containing GABAA receptors: functional selectivity for extra synaptic receptors is dependent on the absence of gamma2. J. Pharmacol. Exp. Ther., 2006, 316: 1351–1359.StorustovuS.I.EbertB.Pharmacological characterization of agonists at delta-containing GABAA receptors: functional selectivity for extra synaptic receptors is dependent on the absence of gamma2J. Pharmacol. Exp. Ther.200631613511359Search in Google Scholar
Thome-Souza S., Klehm J., Jackson M., Kadish N.E., Manganaro S., Fernández I.S. et al.:Clobazam higher-evening differential dosing as an add-on therapy in refractory epilepsy. Seizure, 2016, 1–6. doi 10.1016/j.seizure.2016.05.014. Epub 2016 May 27. PMID: 27281712.Thome-SouzaS.KlehmJ.JacksonM.KadishN.E.ManganaroS.FernándezI.S.Clobazam higher-evening differential dosing as an add-on therapy in refractory epilepsySeizure20161610.1016/j.seizure.2016.05.014Epub 2016 May 27.27281712Open DOISearch in Google Scholar
Vasquez A., Gaínza-Lein M., Sánchez Fernández I., Abend N.S., Anderson A., Brenton J.N. et al.:Pediatric Status Epilepticus Research Group (pSERG). Hospital Emergency Treatment of Convulsive Status Epilepticus: Comparison of Pathways From Ten Pediatric Research Centers. Pediatr. Neurol., 2018, 86: 33–41. doi: 10.1016/j.pediatrneurol.2018.06.004. Epub 2018 Jul 11. PMID: 30075875.VasquezA.Gaínza-LeinM.Sánchez FernándezI.AbendN.S.AndersonA.BrentonJ.N.Pediatric Status Epilepticus Research Group (pSERG). Hospital Emergency Treatment of Convulsive Status Epilepticus: Comparison of Pathways From Ten Pediatric Research CentersPediatr. Neurol.201886334110.1016/j.pediatrneurol.2018.06.004Epub 2018 Jul 11.30075875Open DOISearch in Google Scholar